Got a lovely early Xmas present.
Husband’s relapsed DLCBL has been kicked into remission, with NED on the scan, courtesy of CAR T Therapy and the wonderful team at OUH.
Bless the NHS! I reckon this would’ve cost over $1 million in the US.
Cost to us in the UK? Just our normal taxes etc.

This #WorldLymphomaAwarenessDay, take some time to watch our interview with Paoloc Caimi of @clevelandclinic.bsky.social, in which he outlines the limitations of CAR T-cell therapy for #DLCBL:

🎥 👉 buff.ly/9iQVeyM

#LYMsm #Lymphoma #HemOnc #Hematology #CARTCell #ImmunoOnc #HemeSky

濾胞性リンパ腫(FL)
NHLの20％60代女性
検査所見で軽度LDH↑、可溶性IL-2Rの上昇
病理所見でCD10,19,20,BCL-2の＋
t14,18によるBCL-2の異常発現
3,4期に見つかることが多い、腫瘍量が少なく臓器障害がなければ無治療経過観察、高腫瘍の場合はリツキシマブを含む化学療法

びまん性大型細胞B細胞リンパ腫(DLCBL)
NHLの30％、60代男性、節外変異が40％で多彩な症状
LDH↑、可溶性IL-2R↑
病理所見：びまん性に大型の異形細胞がびまん性に増殖し濾胞構造が破壊、CD19,20＋、CGBとABCの2つのタイプに分かれる、さまざまな亜型がある